NadirAlphaNA EN · DE · ES · FR · 中文 · PL

Integra LifeSciences Stock IART

Integra LifeSciences Holdings Corporation · SEC filings · Reporting currency USD · Quarterly reporting · Figures as of Q2 2026 · events through 2026-10-02 · updated 2026-10-18 · checked 2026-10-14 · ISIN US4579852082

Integra LifeSciences is a global medical technology company that develops, manufactures, and markets surgical instruments, implants, and related products used primarily in neurosurgery, neurocritical care, and reconstructive surgery. Integra LifeSciences stock (IART): Quarterly and annual results since 2023 from Quarterly Report and SEC filings: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 10/2026, quarterly reporting. Stock analysis by NadirAlpha. Integra LifeSciences stock (IART): listed on Nasdaq. NadirAlpha has evaluated 50 original documents, cross-checked every figure automatically and linked each to its source; sources as of 10/2026. Revenue Q2 2026: USD 419 million (+1% year on year). Latest reported (Q2 2026): Consolidated Total Leverage Ratio, Tissue Reconstruction Revenue, Specialty Surgery Revenue. Latest reading: Net income turned positive, Cash flow inflection, Guidance confirmed, Operational disruption.

Net income turned positive Cash flow inflection Guidance confirmed strategy: Operational disruption

NadirAlpha editorial team · About us · Methodology

The new quarter, monitored by AI. · NadirAlpha follows every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.

Integra LifeSciences Current Status

Where Integra LifeSciences stands after the report for Q2 2026: what changed in revenue, earnings and outlook, written editorially from the original report. NadirAlpha methodology

Assessment by NadirAlpha, as of Q2 2026.

Integra LifeSciences disclosed in early October 2026 that a July 2026 flooding event at its Cincinnati manufacturing facility damaged equipment and inventory and disrupted specialty surgical technologies production during 2026-Q3 32. The estimated revenue impact from the event was $7 million in 2026-Q3, with a further $15 to $20 million projected for 2026-Q4, and full manufacturing operations are not expected to resume until Q2 2027 32. As a result, Integra lowered its full-year 2026 revenue guidance from $1.654-$1.695 billion to $1.634-$1.654 billion and cut its adjusted EPS guidance from $2.40-$2.50 to $2.30-$2.40, while confirming full-year operating cash flow guidance of approximately $190-$200 million 32. Integra LifeSciences expects insurance recoveries to mitigate a substantial portion of the earnings impact throughout the recovery period 32.
Management commentary on the 2026-Q3 results (8-K-EX99.1, 2026-10-02):

“Our third quarter results were impacted by the July flooding event at our Cincinnati facility. Our teams have made significant progress executing recovery plans and supporting customers. As we have gained additional visibility into the recovery timeline and production ramp, we now have a clearer understanding of the expected impact on our third quarter results and full-year outlook.”

Stuart Essig, Chairman and Chief Executive Officer 32

“While we are lowering our full-year revenue and adjusted EPS outlook for 2026, we continue to expect strong cash generation, including greater than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year. Importantly, we remain encouraged by the progress we are making across the broader business, including improving product availability, the return of key products to market, and strengthening commercial execution.”

Stuart Essig, Chairman and Chief Executive Officer 32
Revenue · 2026-Q2419$ million+0.8 % vs. 2025-Q2
Net profit · 2026-Q24$ million+100.9 % vs. 2025-Q2
EPS · 2026-Q20.06$+101.0 % vs. 2025-Q2
Revenue trend
Guidance
For FY2026, Integra LifeSciences guides Revenue 1,634 to 1,654 $ million (cut); EPS (non-GAAP) 2.3 to 2.4 $ (cut); operating cash flow 190 to 200 $ million (confirmed). 32 For 2026-Q3, Integra LifeSciences guides Revenue 410 to 425 $ million (initiated); EPS (non-GAAP) 0.53 to 0.61 $ (initiated); organic growth 1.9 to 5.7% (initiated). 31
Profitability
Integra's actual 2026-Q3 financial results had not been reported as of the date of this briefing; formal quarterly figures for operating income, net income, and free cash flow for the period were not yet available. The quarter was characterized by a manufacturing disruption at the Cincinnati facility that weighed on production and gross margin for specialty surgical technologies, contributing to the downward guidance revision for the full year 32. No quarterly income or cash flow figures specific to 2026-Q3 were included in the available disclosures.
Leverage
Integra's most recently disclosed net debt figure, as of 2026-Q2, was 1,565.3 million against a cash balance of 214.4 million; updated Q3 balance sheet data were not yet publicly available at the time of this briefing. The Q3 period saw a significant manufacturing disruption at the Cincinnati facility that may have affected working capital relative to normal operating patterns. No updated net debt or leverage ratio figures specific to 2026-Q3 were included in the available disclosures.
Management view
Integra confirmed its full-year operating cash flow guidance at approximately $190-$200 million despite the Cincinnati manufacturing disruption, indicating the broader cash generation outlook for 2026 remained intact 32. Integra LifeSciences expects insurance recoveries to mitigate a substantial portion of the earnings impact from the flooding throughout the recovery period, providing a partial financial offset to the disruption in both 2026-Q3 and 2026-Q4 32.
Change
A July 2026 flooding event at Integra's Cincinnati manufacturing facility caused damage to equipment and inventory and disrupted specialty surgical technologies production during 2026-Q3 32. The direct revenue impact in the quarter was estimated at $7 million, with an additional $15 to $20 million projected for 2026-Q4 before the facility recovers 32. Full-year 2026 revenue guidance was lowered from $1.654-$1.695 billion to $1.634-$1.654 billion, and adjusted EPS guidance was reduced from $2.40-$2.50 to $2.30-$2.40 32.
Risks (current)
Integra's insurance recovery assessment for the Cincinnati flooding remains ongoing and subject to carrier determination, with future recoveries uncertain in both amount and timing 32. Integra LifeSciences also faces regulatory exposure including challenges in implementing its enterprise-wide Compliance Master Plan and remediating quality systems violations that may affect regulatory approvals, and an ongoing EU MDR certification program that may impact European commercial activities 26 29 30. Integra is further subject to a voluntary global recall of products manufactured at its Boston facility between March 2018 and May 2023, including PriMatrix, SurgiMend, Revize, and TissueMend, as well as 2024 recalls of cottonoid products and MediHoney, and faces potential goodwill and intangible asset impairment charges if acquired businesses underperform 24 26 31.
New this reporting period
Integra announced in October 2026 that its Cincinnati manufacturing facility, which sustained flooding damage in July 2026, is expected to return to full manufacturing operations in Q2 2027, establishing the multi-quarter recovery timeline for specialty surgical technologies production 32. The announcement indicates that disruption effects in the specialty surgical technologies segment will persist through at least the first half of 2027 before normal capacity is restored 32.

Integra LifeSciences Stock: Key Figures ($ million)

NadirAlpha shows fiscal years, half-years and quarters of Integra LifeSciences one below the other, most recently Q2 2026; every figure is clickable and leads to raw value, location and source. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology

All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.

Revenue ($ million) · annual basis, as reported
Net income ($ million) · annual basis, as reported
EPS ($) · annual basis, as reported
Operating cash flow ($ million) · annual basis, as reported
Revenue ($ million) · quarterly basis, as reported
Net income ($ million) · quarterly basis, as reported
EPS ($) · quarterly basis, as reported
Operating cash flow ($ million) · quarterly basis, as reported
Cash ($ million) · annual basis, as reported
Debt ($ million) · annual basis, as reported
Net Debt ($ million) · annual basis, as reported
Capex ($ million) · annual basis, as reported
FCF ($ million) · annual basis, as reported
D&A ($ million) · annual basis, as reported
Cash ($ million) · quarterly basis, as reported
Debt ($ million) · quarterly basis, as reported
Net Debt ($ million) · quarterly basis, as reported
Capex ($ million) · quarterly basis, as reported
FCF ($ million) · quarterly basis, as reported
Shown: the most recent fiscal years. Full history since FY2016 is on record.

Fiscal years

Amounts in $ million · EPS in $ per share · as reported
Integra LifeSciences stock: key figures on annual basis, FY2023 to FY2025, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodRevenueOp. incomeNet incomeEPS ($)EPS adj. ($)EBITDA (adj.)OCFSource
FY20251,635.2-493.4-516.5-6.742.23317.550.4131
FY20241,610.528.4-6.9-0.092.56322.2129.4127
FY20231,541.6111.567.70.843.10369.7140119

Quarters

Amounts in $ million · EPS in $ per share · as reported
Integra LifeSciences stock: key figures on quarterly basis, 2023-Q1 to 2026-Q2, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodPublishedRevenueOp. incomeNet incomeEPS ($)EPS adj. ($)EBITDA (adj.)FCFCashNet DebtSource
2026-Q2*2026-07-29418.819.34.50.060.5678.410.5214.41,565.3131
2026-Q1*2026-05-05391.911.5-4.6-0.060.5476.2-5236.81,552.2129
2025-Q4*2026-02-26434.923-1.7-0.02*≈0.83104.2-5.42351,533.3127
2025-Q3*2025-10-30402.111.8-5.4-0.070.5478.525.8232.21,515.4125
2025-Q2*2025-07-31415.6-512.7-484.1-6.310.4571.2-11.2217.91,474.922
2025-Q1*2025-05-05382.7-15.5-25.3-0.330.4163.6-40.2239.11,463.3121
2024-Q4*2025-02-25442.635.619.40.25*≈0.97104.921.1246.41,414.718
2024-Q3*2024-11-04380.8-8.2-10.7-0.140.4161.8-7.2215.21,489.616
2024-Q2*2024-07-29418.2-3-12.4-0.160.6383.810.7215.2960.614
2024-Q1*2024-05-06368.94-3.3-0.040.5571.80.3591.9598.5113
2023-Q4*2024-02-283973619.80.250.89100.534.2276.4563.710
2023-Q3*2023-10-25382.426.619.50.240.7688.113.7273.75868
2023-Q2*2023-07-27381.312.54.20.050.7188.812.6309.2460.36
2023-Q1*2023-04-26380.836.424.20.290.7492.312.5307.4461.8~105
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
Columns not reported in this reporting cadence are hidden: Op. income (adj.) (not reported in any source for these periods).

Integra LifeSciences Balance Sheet & Cash Flow ($ million)

NadirAlpha places cash, debt, operating cash flow and investments of Integra LifeSciences side by side per period, balance sheet values as of the period end, flow items for the period. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology

Fiscal years

Amounts in $ million · as reported
Integra LifeSciences stock: balance sheet and cash flow on annual basis, FY2023 to FY2025, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodPublishedCashDebtNet DebtD&AOCFCapexFCFSource
FY20252026-02-262351,768.31,533.359.850.481.4-31.1131
FY20242025-02-25246.41,661.11,414.763.7129.4104.425127
FY20232024-02-28276.4840.1563.753.314066.973.1119

Quarters

Amounts in $ million · as reported
Integra LifeSciences stock: balance sheet and cash flow on quarterly basis, 2023-Q1 to 2026-Q2, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodPublishedCashDebtNet DebtOCFCapexFCFSource
2026-Q22026-07-29214.41,779.71,565.322.812.310.5131
2026-Q12026-05-05236.81,7891,552.29.814.8-5129
2025-Q42026-02-262351,768.31,533.311.817.2-5.4127
2025-Q32025-10-30232.21,747.61,515.440.915.225.8125
2025-Q22025-07-31217.91,692.81,474.98.920.1-11.222
2025-Q12025-05-05239.11,702.41,463.3-11.328.9-40.2121
2024-Q42025-02-25246.41,661.11,414.750.729.621.118
2024-Q32024-11-04215.21,704.71,489.622.529.6-7.216
2024-Q22024-07-29215.21,175.9960.640.429.710.714
2024-Q12024-05-06591.91,190.4598.515.815.50.3113
2023-Q42024-02-28276.4840.1563.758.824.634.210
2023-Q32023-10-25273.7859.858626.813.113.78
2023-Q22023-07-27309.2769.5460.328.315.612.66
2023-Q12023-04-26307.4769.1~461.8~26.213.712.5105
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.

Integra LifeSciences Guidance Tracking (latest per metric/period · 25/46)

What Integra LifeSciences guided for Q2 2026 and beyond and whether the targets were met; ranges count as met when the actual lies within. NadirAlpha methodology

Actuals: revenue in $m · EPS in $ per share · ratios in %

Direction: confirmedcutinitiated Verdict: beatin linemisspending

Integra LifeSciences: guidance and actuals per metric and period, 46 entries. Compiled by NadirAlpha from SEC filings.
For periodGuided onMetricGuidedActualVerdictDirectionSource
FY20262026-10-02Revenue1,634–1,654–32
FY20262026-10-02EPS (non-GAAP)2.3–2.4–32
FY20262026-10-02operating cash flow190–200–32
FY20262026-07-29organic revenue growth0.8–3.3%–31
2026-Q32026-07-29Revenue410–425–31
2026-Q32026-07-29EPS (non-GAAP)0.53–0.61–31
2026-Q32026-07-29organic growth1.9–5.7%–31
2026-Q22026-05-05Revenue410–425418.829
2026-Q22026-05-05EPS (non-GAAP)0.44–0.520.5629
2026-Q12026-02-26Revenue375–390391.927
2026-Q12026-02-26EPS (non-GAAP)0.37–0.450.5427
FY20252025-10-30Revenue1,620–1,6401,635.225
FY20252025-10-30EPS (non-GAAP)2.19–2.242.2325
FY20252025-02-25Revenue growth (YoY)2.4–6.5%1.519
FY20252025-02-25organic growth1–5%––19
2025-Q42025-10-30Revenue420–440434.925
2025-Q42025-10-30EPS (non-GAAP)0.79–0.840.8325
2025-Q32025-07-31Revenue410–420402.123
2025-Q32025-07-31EPS (non-GAAP)0.4–0.450.5423
2025-Q22025-05-05Revenue390–400415.621
2025-Q22025-05-05EPS (non-GAAP)0.4–0.450.4521
2025-Q12025-02-25Revenue375–385382.719
2025-Q12025-02-25EPS (non-GAAP)0.4–0.450.4119
2025-Q12025-02-25Revenue growth (YoY)1.6–4.4%3.719
2025-Q12025-02-25organic growth-6.2–-3.5%––19
FY20242024-11-04Revenue1,609–1,6191,610.517
FY20242024-11-04EPS (non-GAAP)2.41–2.492.5617
FY20242024-02-28Organic growth4–5%––11
2024-Q42024-11-04Revenue441–451442.617
2024-Q42024-11-04EPS (non-GAAP)0.81–0.890.9717
2024-Q32024-07-29Revenue372–382380.815
2024-Q32024-07-29EPS (non-GAAP)0.36–0.440.4115
2024-Q22024-05-06Revenue411–416418.213
2024-Q22024-05-06EPS (non-GAAP)0.6–0.650.6313
2024-Q12024-02-28Revenue360–365368.911
2024-Q12024-02-28EPS (non-GAAP)0.53–0.570.5511
FY20232023-10-25Revenue1,541–1,5471,541.69
FY20232023-10-25EPS (non-GAAP)3.1–3.143.19
2023-Q42023-10-25Revenue397–4033979
2023-Q42023-10-25EPS (non-GAAP)0.89–0.930.899
2023-Q32023-07-27Revenue386–390382.47
2023-Q32023-07-27EPS (non-GAAP)0.76–0.80.767
2023-Q22023-04-26Revenue396–400381.35
2023-Q22023-04-26EPS (non-GAAP)0.75–0.790.715
2023-Q12023-02-22Revenue370–376380.83
2023-Q12023-02-22EPS (non-GAAP)0.72–0.760.743

Integra LifeSciences Stock: Price & Chart

Price history of Integra LifeSciences stock (IART) as a TradingView chart, loaded only after a click, alongside the trend of the key figures from the tables. NadirAlpha methodology

Daily candles with news and earnings markers. Loads only on click.

Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.

Integra LifeSciences Event Timeline

NadirAlpha sorts 57 events of Integra LifeSciences by quarter, most recent first, each with source number and event type, management quotes as direct quotes at the start of the quarter. NadirAlpha methodology

Overview: one dot per event · click jumps to the period
earningsrevenuemarginguidancestrategyfinancials2023-Q12023-Q22023-Q32023-Q42024-Q12024-Q22024-Q32024-Q4FY20242025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q3
2026 · 9 events

Guidance cut 2026-10-02
Full-year revenue guidance lowered to $1.634 to $1.654 billion and adjusted EPS guidance cut from $2.40 to $2.50 to $2.30 to $2.40, reflecting Cincinnati flood impact of approximately $7 million on Q3 revenues and $15 to 20 million expected in Q4, with facility return to full operations not anticipated until Q2 2027 32
Guidance confirmed 2026-10-02
Full-year operating cash flow guidance confirmed at approximately $190 to $200 million despite flood-related revenue impacts 32

“Our second-quarter performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year.”

Stuart Essig, Chairman and CEO 31
Operational disruption 2026-07-29
Cincinnati, Ohio manufacturing facility sustained flood damage on July 17, 2026, causing equipment and inventory damage and disrupting specialty surgical technologies production; no material adverse effect expected based on initial assessment 30
Net income turned positive 2026-07-29
GAAP net income of 4.5 million versus net loss of $484.1 million in Q2 2025, primarily due to absence of prior-year goodwill impairment charge 30
Guidance confirmed 2026-07-29
Full-year organic revenue growth guidance of 0.8%–3.3% and adjusted EPS guidance of $2.40 to $2.50 reaffirmed; reported revenue guidance narrowed to $1.654 to $1.695 billion to reflect stronger U.S. dollar impact 31
Cash flow inflection 2026-07-29
Operating cash flow reached USD 22.8 million vs USD 8.9 million in 2025-Q2 (×2.6). 131

“Our first‑quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold.”

Mojdeh Poul, President and Chief Executive Officer 29
Revenue accelerating ◦ 2026-05-05
Q1 revenues of 391.9 million, reported growth 2.4% and organic growth 1.3%, as quality and operational issues reduced compared to the prior year 29
Margin expanding 2026-05-05
Gross margin increased to 55.4% from 50.8% year-over-year, primarily attributable to higher revenues and reduction in Braintree remediation costs 28
Guidance raised 2026-05-05
2026 adjusted EPS guidance raised from $2.30 to $2.40 to $2.40 to $2.50, reflecting Q1 benefits from IEEPA tariffs; full-year revenue guidance reaffirmed at $1.662 to $1.702 billion 29
2025 · 13 events

“Earlier this month we implemented a key element of our transformation plan, a simplified operating model that improves alignment, execution, and accountability. This is critical to our long-term margin improvement plan and a key contributor to our previously communicated savings of $25-$30 million in 2026. Combined with focused portfolio prioritization and disciplined capital allocation, these actions reinforce the foundation for long-term sustainable growth, innovation, and performance.”

Mojdeh Poul, president and chief executive officer 27
Revenue decelerating ◦ 2026-02-26
Q4 revenues of $434.9M declined 1.7% reported and 2.5% organically; Tissue Technologies fell 12.8% including Wound Reconstruction down 21.4% 27
Guidance initiated 2026-02-26
2026 full-year revenue guidance of $1,662-$1,702M (1.6%-4.1% reported growth) and adjusted EPS of $2.30-$2.40 issued 27
Strategic pivot 2026-02-26
Simplified operating model implemented with restructuring initiative approved in Q4 2025 targeting $25-$30M in cost savings in 2026 through productivity and efficiency initiatives 27

“In the third quarter, we continued to see healthy demand across our portfolio. While revenue was impacted by two supply interruptions, we delivered strong profitability and cash flow through disciplined cost management and operational efficiencies. We are making progress in implementing our comprehensive plan to systematically strengthen the entirety of our supply chain and quality management system, and we remain confident in our strategy to improve overall performance and drive the Company's transformation.”

Mojdeh Poul, president and chief executive officer 25
earnings 2025-10-30
Adjusted EBITDA increased to $78.5M (19.5% of revenue) from $61.8M (16.2% of revenue) in Q3 2024 25
Revenue accelerating ◦ 2025-10-30
Q3 revenues of $402.1M increased 5.6% reported and 5.0% organically, reversing negative organic trends from the prior two quarters 25
Guidance cut 2025-10-30
2025 full-year guidance revised to reflect Q3 revenue and updated Q4 assumptions; full-year actuals of $1,635.2M came in below the $1.655-$1.680B range set at Q2 25
Operating income turned positive 2025-10-30
Operating income turned positive for the first time after 2 negative periods (-512.7 to +USD 11.8 million). 125

“I am proud of our team's performance and execution in the second quarter. Our strong revenue performance is a testament to our disciplined progress and the solid underlying demand trends for our portfolio of neurosurgery and tissue technology products.”

Mojdeh Poul, President and Chief Executive Officer 23
earnings 2025-07-31
GAAP net loss of $484.1M in Q2 2025 primarily driven by $511.4M goodwill impairment across Tissue Technologies, Neurosurgery, and Instruments and ENT reporting units due to share price decline and operational challenges 23
Margin compressing 2025-07-31
Adjusted gross margin declined to 60.7% from 65.2% in Q2 2024; adjusted EBITDA margin fell to 17.1% from 20.0% due to quality and operational issues 23
Guidance cut 2025-07-31
Full-year revenue guidance updated to $1.655-$1.680B; adjusted EPS range reflecting ongoing quality and operational headwinds 23

“As I reflect on my first quarter at Integra and continue spending time across our operations and with employees, I remain inspired by the deep commitment of our teams to our customers and patients. I am also encouraged by the positive feedback I consistently receive from customers about the impact of our solutions and the value of our portfolio. I'm equally optimistic about the long-term growth and earnings potential of our differentiated offerings.”

Mojdeh Poul, President and Chief Executive Officer 21
Revenue decelerating ◦ 2025-05-05
Q1 revenues of $382.7M grew 3.7% reported but declined 3.5% organically; Neurosurgery fell 4.7% organically on shipping holds and Tissue Technologies declined 9.1% organically due to quality and operational issues 21
Margin compressing 2025-05-05
Gross margin declined to 50.8% from 56.1% in Q1 2024; adjusted gross margin declined to 62.2% from 64.4%, both impacted by quality and operational issues 20 21
Guidance cut 2025-05-05
Full-year adjusted EPS guidance reduced to $2.19-$2.29, including estimated tariff impact of $(0.22) per share 21
2024 · 17 events

Operating income halved 2025-02-25
Operating income more than halved YoY (111.5 to USD 28.4 million, -75%). 18

“As I step into my role leading Integra, I am inspired by the strength of our portfolio, the dedication of our team, and the tremendous potential we have to grow and innovate in high-impact specialty markets. Our fourth-quarter results reflect this strength, with sequential revenue growth driven by robust demand for our leading brands, continued progress in expanding our global presence, and our ongoing commitment to improving supply reliability.”

Mojdeh Poul, President and Chief Executive Officer 19
Revenue accelerating ◦ 2025-02-25
Q4 revenues of $442.6 million increased 3.5% on an organic basis, recovering from Q3 disruptions as shipping holds released in line with expectations 19
Strategic pivot 2025-02-25
FDA issued a warning letter in December 2024 relating to quality system issues at three manufacturing facilities (Mansfield, Plainsboro, Princeton) 18
Acquisition 2025-02-25
Acquired product rights for Durepair Regeneration Matrix from Medtronic for $45.0 million total consideration, expanding the neurosurgery portfolio 18
Operating income turned positive 2025-02-25
Operating income turned positive for the first time after 2 negative periods (-8.2 to +USD 35.6 million). 127
Net income turned positive 2025-02-25
Net income turned positive for the first time after 3 negative periods (-10.7 to +USD 19.4 million). 127

“Our third-quarter results highlight the early progress we are making to identify and remediate the gaps in our quality management system. We are progressing with the implementation of our compliance master plan across our manufacturing and supply chain operations, which will position us to meet robust market demand and more consistently and reliably deliver to customers, patients, and shareholders.”

Jan De Witte, President and CEO 17
Revenue decelerating ◦ 2024-11-04
Q3 revenues declined 8.6% on an organic basis; Neurosurgery declined 16.0% organically due to temporary shipping holds in CSF management and neuro monitoring 17
Margin compressing 2024-11-04
Gross margin fell to 52.6% from 57.1% in Q3 2023; adjusted EBITDA margin declined to 16.2% of revenue from 23.0%, driven by quality and operational disruptions 16 17
Strategic pivot 2024-11-04
Mojdeh Poul announced as incoming President and Chief Executive Officer, joining January 6, 2025 17

“Our second quarter financial performance continues to reflect the persistent market demand for our diversified portfolio and the commitment of our teams. Using the learnings from our Boston facility, we are continuing a thorough analysis of our operations and are committed to enhancing the quality, reliability and resilience of our manufacturing operations and supply chain. The reduction in our full-year guidance reflects an updated view of our operational challenges and critical investments in our compliance improvement program that will allow our supply to meet our strong commercial demand strength over time.”

Jan De Witte, President and Chief Executive Officer 15
Guidance cut 2024-07-29
Full-year 2024 revenue guidance reduced to $1.609 to 1.629 billion from the $1.672 to 1.687 billion level set in Q1, reflecting shipping hold volume losses and significant second-half quality compliance investments 15
Strategic pivot 2024-07-29
Compliance Master Plan initiated as a systematic quality and GMP remediation approach; temporary shipping holds placed on certain products expected to primarily impact Q3 revenues 15
Acquisition 2024-07-29
Acclarent, Inc. acquired from Ethicon for approximately $282 million, establishing Integra as a leading ENT provider; Acclarent contributed $31.3 million to Codman Specialty Surgical revenue in Q2 14
Revenue accelerating 2024-07-29
Revenue growth accelerated to +9.7% YoY (prior period -3.1%). 123

“We are pleased with our strong first quarter financial performance, which reflects the strength of our diversified portfolio and the unwavering commitment of our colleagues worldwide to our customers and patients. As we look to the rest of the year, we remain focused on executing our key priorities, particularly on enhancing quality, reliability and resilience of our manufacturing operations and supply chain, advancing our new product pipeline, and integrating the Acclarent business and welcoming our new colleagues.”

Jan De Witte, president and chief executive officer 13
Revenue decelerating ◦ 2024-05-06
Q1 revenues declined 3.1% reported and 2.5% organic, with the Boston facility recall depressing results by $15.2 million; organic growth excluding Boston impact was +1.6% 13
Margin compressing 2024-05-06
Gross margin fell to 56.1% from 61.1% in Q1 2023, driven by idle capacity costs and elevated manufacturing expenses at the Boston facility 12
Guidance raised 2024-05-06
Full-year 2024 revenue guidance raised to $1.672 to 1.687 billion from $1.603 to 1.618 billion, adding approximately $80 million for the Acclarent acquisition 13
Operating income halved 2024-05-06
Operating income more than halved YoY (36.4 to USD 4.0 million, -89%). 12
2023 · 18 events

“In 2023, we saw stability in our markets and resilience of our product portfolio, which demonstrates the impact of our products and technologies on restoring patients' lives. Despite the operational challenges last year, I am extremely proud of our colleagues around the world for remaining focused on advancing our key pillars of growth and operational excellence, and for their unwavering commitment to our customers and patients.”

Jan De Witte, President and Chief Executive Officer 11
Margin compressing 2024-02-28
FY2023 adjusted EBITDA $369.7 million, down $41.6 million versus prior year; adjusted EBITDA margin declined 240 basis points to 24.0% 11
Guidance initiated 2024-02-28
2024 guidance: revenues $1,603-$1,618 million (4.0-5.0% reported growth); adjusted EPS $3.15-$3.25 11
Acquisition 2024-02-28
Signed definitive agreement to acquire Acclarent ENT business from Johnson & Johnson for $275 million cash plus up to $5 million in regulatory milestone payments 11
Net income halved 2024-02-28
Net income more than halved YoY (52.9 to USD 19.8 million, -63%). 119

“Although the Boston returns weighed further on our third quarter results, we are on track to restart the Boston facility by the end of the year, and we also met two significant CereLink milestones with the relaunch in international markets and submission for regulatory approval in the U.S. At the same time, our strong organic growth performance in the Codman Specialty Surgical and Tissue Technologies businesses, excluding Boston, plus advances across our product pipeline, give us confidence in our long-range growth commitments.”

Jan De Witte, President and Chief Executive Officer 9
Revenue decelerating ◦ 2023-10-25
Q3 revenues declined 0.7% reported and 0.4% organic; Tissue Technologies revenues fell 15.6% to $114.2 million due to Boston recall impact 9
Margin compressing 2023-10-25
Adjusted gross margin declined to 64.6% from 66.7% in the prior year; adjusted EBITDA declined to $88.1 million from $105.3 million 9
Guidance cut 2023-10-25
Full-year 2023 guidance revised to $1.541-$1.547 billion revenue and adjusted EPS $3.10-$3.14, from prior ranges of $1,602-$1,620 million and $3.43-$3.51 9
Operating income halved 2023-10-25
Operating income more than halved YoY (65.0 to USD 26.6 million, -59%). 117
Net income halved 2023-10-25
Net income more than halved YoY (49.9 to USD 19.5 million, -61%). 117

“The strong organic growth of our Codman Specialty Surgical segment and several product lines in our Tissue Technologies business demonstrate the resilience of our diversified portfolio of leading brands and technologies and strong market recovery. Excluding the impact of the Boston recall, we delivered solid, mid-single digit organic growth from the underlying business. We are confident in our plans for the CereLink relaunch and the restart of our Boston manufacturing facility, and we continue to advance our implant-based breast reconstruction (IBBR) PMA strategy.”

Jan De Witte, President and Chief Executive Officer 7
Revenue decelerating ◦ 2023-07-27
Q2 revenues declined 4.2% reported and 2.7% organic; Tissue Technologies revenues fell 21.2% reported and 19.7% organic due to Boston recall impact 7
Margin compressing 2023-07-27
H1 gross margin percentage declined to 57.7% from 62.4% in the prior year period due to Boston recall expenses 6
Strategic pivot 2023-07-27
Voluntary recall of Boston facility products (March 2018-May 2023) initiated in May 2023; manufacturing halt extended; $12.9 million return provision and $24.1 million inventory write-off recorded 6
Operating income halved 2023-07-27
Operating income more than halved YoY (59.9 to USD 12.5 million, -79%). 115
Net income halved 2023-07-27
Net income more than halved YoY (44.8 to USD 4.2 million, -91%). 115
Segment divergence 2023-07-27
Tissue Technologies revenue grew +73.5% to USD 242.9 million in 2023-Q2 (64% of group revenue) while group revenue changed -4.1%. 6

“Our first quarter sales performance continues to demonstrate the strength of our diverse portfolio. We experienced solid growth and demand across many of our product lines and saw positive dynamics in our markets. We remain focused on delivering profitable growth while making critical investments to support our long-term strategic objectives and commitments.”

Jan De Witte, president and chief executive officer 5
Revenue accelerating ◦ 2023-04-26
Q1 revenues increased 1.1% reported and 4.6% organic; Codman Specialty Surgical +3.5% organic, Tissue Technologies +6.8% organic 5
Guidance confirmed 2023-04-26
Full-year 2023 revenue guidance of $1,602-$1,620 million and adjusted EPS $3.43-$3.51 reaffirmed 5
Strategic pivot 2023-04-26
Production at Boston manufacturing site paused in March while quality system upgrades were pulled forward into H1 2023 5

Integra LifeSciences Business Model

How Integra LifeSciences (IART) makes its money, summarised from the filings up to Q2 2026, neutral and without forecast. NadirAlpha methodology

Integra LifeSciences is a global medical technology company that develops, manufactures, and markets surgical instruments, implants, and related products used primarily in neurosurgery, neurocritical care, and reconstructive surgery. Integra LifeSciences distributes its products to hospitals, ambulatory surgery centers, and healthcare professionals through a direct sales force and distributor network across the United States and internationally. Integra's portfolio spans dural regeneration and repair matrices, cerebrospinal fluid management systems, ultrasonic surgical aspiration systems, cranial stabilization and positioning devices, and wound reconstruction products. Revenue is generated through direct sales of both capital equipment and single-use implant and instrument formats; the company does not report a distinct recurring-revenue segment in its public financial disclosures.

Integra LifeSciences Stock: Share-Price Drivers

The drivers of Integra LifeSciences stock from the company's perspective: demand, prices, costs and capacity as the investor relations reports describe them. NadirAlpha methodology

Manufacturing remediation and the sequential restart of recalled or disrupted facilities (Boston, Braintree, Cincinnati)
Integra's revenue has been held back by product recalls and manufacturing disruptions; quarterly revenue was 418.8 million in 2026-Q2 (131), and recovery of the Cincinnati manufacturing facility is expected only in 2027-Q2 (32), leaving a multi-quarter overhang on supply, product availability and growth (26).
Facility remediation and manufacturing restarts
Integra restarted Braintree production in Q2 2026 (31) and began operationalizing the Braintree facility in mid-2026 (28), while Cincinnati manufacturing recovery is expected in 2027-Q2 (32); the earlier Boston facility voluntary recall dated to May 2023 (26), so traction depends on these restarts holding.
SurgiMend and DuraSorb breast-reconstruction pipeline
Integra targets SurgiMend PMA approval in the first half of 2026 (30) with a relaunch slated for Q4 2026 (31), and DuraSorb PMA approval for breast reconstruction expected in 2027 (28); these regenerative-tissue products are positioned for implant-based breast reconstruction (26) but remain pre-launch, so traction is not yet demonstrated.
Neurosurgery and ENT (Codman Specialty Surgical) franchises
Integra's Neurosurgery line reported FY2025 revenue of 827.7 million at 3.0% (27); within Codman Specialty Surgical, ENT revenue reached 166.4 million, up 22.7% (27), supported by the Acclarent acquisition (26), indicating the ENT line is gaining traction.
Tissue Technologies and wound-care weakness
Integra's Tissue Technologies segment posted FY2025 revenue of 434.7 million at -6.9% (27), with Wound Reconstruction and Care at 323.5 million, down -7.7%, and Private Label at 111.2 million, down -4.4% (27).
CereLink intracranial pressure monitor relaunch
Integra completed the CereLink global relaunch in Q1 2024 (11) following the CereLink Monitor FDA 510(k) clearance on February 4, 2024 (10), after the 2022 voluntary product removal (10); the company also brought Durepair and PriMatrix back to market in 2026-Q1 (29).
Decelerating growth, reduced guidance and elevated leverage
Growth is decelerating and guidance was cut; 2026-Q2 revenue was 418.8 million against 434.9 million in 2025-Q4 (127), 2026-Q2 operating income was 19.3 million (131), and net debt stood at 1,565.3 million (131).

Sector trend: In the neurosurgery and regenerative-tissue medical-device space, Integra's figures point to mixed demand and thin margins: neurosurgery and ENT revenue are higher while tissue and wound-care lines are lower (27), and company guidance was cut. Operating income was 19.3 million in 2026-Q2 (131), indicating pressured profitability while manufacturing capacity is rebuilt (32).

Integra LifeSciences Revenue by Type (as of 2026-Q2 · USD million · 9/9)

The segments of Integra LifeSciences in the company's own definition, each row with its basis (3, 6 or 12 months), rows in grey are no longer reported separately. NadirAlpha methodology

Integra LifeSciences: revenue by segment, as of 2026-Q2, in USD million. Compiled by NadirAlpha from SEC filings.
SegmentSinceRevenueGrowthSource
Period 2026-Q1 (3M)
Specialty Surgery2026-Q1283.10.9%29
Tissue Reconstruction2026-Q1108.86.7%29
Period FY2025 (12M)
ENT2024-Q3166.422.7%27
Neurosurgery2023-Q4827.73%27
Wound Reconstruction and Care2023-Q4323.5-7.7%27
Instruments2023-Q4206.51.1%27
Private Label2023-Q4111.2-4.4%27
Codman Specialty Surgical2022-Q21,200.55%27
Tissue Technologies2022-Q2434.7-6.9%27

Integra LifeSciences Products & announcements (21/61 active+recent)

What Integra LifeSciences launched, had approved or announced, from the filings up to Q2 2026, each row with the date of first mention. NadirAlpha methodology

Status: PlannedLaunched

Integra LifeSciences: product announcements from the filings, 61 entries. Compiled by NadirAlpha from SEC filings.
Product/LineSinceStatusSource
2026
SurgiMend relaunch2026-1231
SurgiMend production2026-1229
Durepair return to market (2×)2026-0329
Simplified operating model implementation2026-0227
DuraSorb PMA approval for multiple indications for IBBR202624
2025
CUSA Clarity for Cardiac Surgery2025-1130
PriMatrix relaunch2025-0925
Mayfield Ghost Base Unit Post (2×)2025-0930
Durepair relaunch2025-0925
AERA Pediatric Registry (3×)2025-0726
Profitability Initiative2025-0623
Early relaunch of PriMatrix202527
Early relaunch of Durepair202527
CerebroFlo EVD catheter with Endexo technology202526
CereLink approval in Brazil, Philippines, UAE, Albania and India202524
Aurora Surgiscope 15mm x 60mm and 15mm x 80mm (2×)202526
2024
Braintree facility operational (11×)2024-0628
2023
DuraSorb approval2023-0930
Aurora Surgiscope next generation (2×)2023-0924
SurgiMend PMA approval (3x)2023-0630
2021
SurgiMend breast reconstruction PMA filing (8×)2021-0922
2024
SurgiMend PMA approvable notification pending GMP certification2024-1219
DuraSorb PMA submission advancement2024-1219
CereLink market uptake2024-1219
Braintree facility equipment installation2024-0917
SurgiMend® PRS pre-market approval2024-0614
Boston facility relaunch2024-0611
SurgiMend and PriMatrix relaunch2024-0313
MicroMatrix® Flex launch in U.S.2024-0314
MicroMatrix Flex U.S. commercial availability2024-0312
CereLink intracranial pressure monitoring system relaunch2024-0318
CereLink Monitor FDA 510(k) clearance (2×)2024-0210
MicroMatrix Flex U.S. launch202422
2023
Boston manufacturing facility restart2023-129
9mm Surgiscope FDA 510(k) clearance (2×)2023-1010
SurgiMend PMA supplement submission2023-095
CereLink 510(k) premarket notification2023-099
CUSA Electrosurgery Module launch (2×)2023-0810
CereLink ICP Monitor international limited release2023-0710
DuraSorb IDE clinical study (5x)2023-0610
DuraGen portfolio expansion (China and Japan approvals)2023-067
Boston facility product recall (3x)2023-0526
DuraSorb PMA clinical trial2023-035
MicroMatrix and Certas Plus Programmable Valve launch in Europe2023-0110
Cytal launch in Europe2023-0110
MicroMatrix launch in Europe202310
MicroMatrix Flex202324
MicroMatrix20236
DuraGen Secure approval in Japan202312
DuraGen Secure20236
DuraGen Plus20236
Cytal and MicroMatrix Europe launch202312
Certas Plus approval in China (2x)202324
Certas Plus Programmable Valve launch in Europe202310
Certas Plus Programmable Valve20236
Acclarent AERA Eustachian Tube Dilation System expanded pediatric indications 510(k) clearance202324
2022
CereLink relaunch (8x)2022-087
Neutus EVD system launch in China2022-064
NeuraGen 3D Nerve Guide Matrix launch202212
CUSA Lap Tip launch (9×)20228
Aurora Evacuator with Coagulation device launch20224

Integra LifeSciences Transactions & Events (11)

11 transactions and events of Integra LifeSciences from the original reports, financing measures and management changes are not listed here, cancelled items in grey. NadirAlpha methodology

Acquisitions · 7Divestitures/exits · 2older: 2 (in the table)
2021202220232024

Acquisitions by Integra LifeSciences

Integra LifeSciences: Acquisitions, 9 entries. Compiled by NadirAlpha from SEC filings.
Transaction / stakeDateTypeSource
2024
Acclarent ENT acquisition (3×)2024-06Completed11
Acclarent2024-04Completed26
Durepair Dural Regeneration Matrix (6×)2024Completed26
2023
Acclarent acquisition from Ethicon, Inc. (2×)2023-12Completed14
2022
Surgical Innovation Associates (3×)2022-12Completed10
SIA acquisition2022-12Completed10
2021
ACell, Inc. acquisition2021-01Completed10
2019
Rebound Therapeutics Corporation acquisition2019-01Completed10
Arkis Biosciences, Inc. acquisition2019-01Completed10

Divestitures and exits by Integra LifeSciences

Integra LifeSciences: Divestitures / exits, 2 entries. Compiled by NadirAlpha from SEC filings.
Transaction / stakeDateTypeSource
2022
TWC business divestiture to Gentell Inc. (3×)2022-08Divested10
CereLink product removal2022-08Divested12

Integra LifeSciences Risks (100 since the annual report of 2026-02-26, 257 tracked in total)

Risk factors Integra LifeSciences itself names in its reports, merged by topic across periods, with category, first mention and source; new risks of the latest period come first. NadirAlpha methodology

Category: CyberFinancialCustomersCompetitionSupply chainMacroRegulatoryLegalPeopleGeopoliticsTechnologyESG

Integra LifeSciences: risk factors as reported, 100 since the last annual report, 257 tracked. Compiled by NadirAlpha from SEC filings.
RiskCategoryLast reported
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2026-07-29 (2026-Q2), source 31
Breaches or disruptions of company's or vendors' information technology systems=
Difficulties controlling expenses including product procurement and manufacturing costs=
Geographic distribution of taxable income and tax law changes=
Company's ability to accurately predict demand for products and product development=
Coverage and reimbursement decisions by third-party payors; trends toward health care cost containment=
Increasing industry competition=
Integra LifeSciences: first mention in 10-Q quarterly report of 2026-07-29 (2026-Q2), source 30
July 2026 flood damage at Cincinnati facility; assessment ongoing for financial impact=
U.S. tariffs on imports; Company submitted $17.6M refund claims; costs passed to COGS=
Geopolitical tension and trade barriers may impact suppliers, vendors and customers=
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2026-05-05 (2026-Q1), source 29
Interest rate and foreign currency rate fluctuations impact on business2026-Q2
2026-07-29 31
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2026-02-26 (2025-Q4), source 27
Company's ability to remediate quality systems violations and implement compliance master plan2026-Q2
2026-07-29 31
Integra LifeSciences: first mention in 10-K annual report of 2026-02-26 (FY2025), source 26
Prior quality issues led to voluntary global recall of Boston facility products through May 20232026-Q2
2026-07-29 30
Integra LifeSciences: first mention in 10-Q quarterly report of 2025-07-31 (2025-Q2), source 22
FDA warning letters at three facilities; PMA approvals blocked until violations resolved2026-Q2
2026-07-29 30
Consolidated Total Leverage Ratio at 4.10 versus covenant requirement of 5.002026-Q2
2026-07-29 30
Integra LifeSciences: first mention in 10-Q quarterly report of 2025-05-05 (2025-Q1), source 20
Potential difficulties, delays and disruptions in manufacturing, distribution or sale of products2026-Q2
2026-07-29 31
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2025-02-25 (2024-Q4), source 19
Difficulties obtaining and maintaining required regulatory approvals; EU Medical Device Regulation compliance2026-Q2
2026-07-29 31
Impact of management and organizational changes on business execution2026-Q2
2026-07-29 31
Integra LifeSciences: first mention in 10-K annual report of 2025-02-25 (FY2024), source 18
Increased geopolitical instability, trade barriers, tariffs, armed conflict affecting suppliers and operations2026-Q2
2026-07-29 31
Integra LifeSciences: first mention in 10-K annual report of 2024-02-28 (FY2023), source 10
Supply chain disruptions and vendor/supplier ability to meet contractual obligations2026-Q2
2026-07-29 31
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2023-07-27 (2023-Q2), source 7
Potential goodwill and intangible asset impairment charges if acquired businesses underperform2026-Q2
2026-07-29 31
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2023-04-26 (2023-Q1), source 5
Ongoing EU MDR certification program may impact European commercial activities2026-Q2
2026-07-29 30
Integra LifeSciences: first mention in 10-Q quarterly report of 2023-04-26 (2023-Q1), source 4
Supply chain disruptions and tariffs may increase product costs and impact demand2026-Q2
2026-07-29 30
Increasing industry competition and market consolidation2026-Q2
2026-07-29 30
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2026-10-02, source 32
Insurance recovery assessment ongoing; future recoveries uncertain and subject to carrier assessment.=
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2026-05-05 (2026-Q1), source 29
Difficulties in controlling expenses including procurement and manufacturing costs.=
Coverage and reimbursement decisions of third-party payors and healthcare cost containment trends affect business.=
Fluctuations in foreign currency exchange rates impact financial results.=
Impact of changes in management or staff levels and ability to manage organizational changes.=
Changes to applicable tax laws and global healthcare reforms may impact business.=
Breaches, failures or disruptions of company or vendors' or customers' information technology systems.=
Increasing industry competition may impact market position.=
Anticipated development of markets and success of company products in these markets are uncertain.=
Integra LifeSciences: first mention in 10-Q quarterly report of 2026-05-05 (2026-Q1), source 28
Compliance Master Plan implementation ongoing to remediate quality gaps across manufacturing and supply network.=
FDA warning letters restrict PMA approvals for Class III devices until quality system violations resolved.=
Ongoing trade policy uncertainty with new tariff measures being proposed, paused, and implemented.=
Potential exposure to litigation and regulatory proceedings affecting business operations.=
Difficulties or delays in obtaining and maintaining required regulatory approvals.=
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2026-02-26 (2025-Q4), source 27
MediHoney and Integra Skin remediation efforts impacting Wound Reconstruction sales=
Amount of bank borrowings and liquidity management=
Fluctuations in foreign currency exchange rates impacting results=
Failure of suppliers and vendors to meet contractual and regulatory obligations=
Breaches and failures of information technology systems and products=
Increasing industry competition in medical technology markets=
Integra LifeSciences: first mention in 10-K annual report of 2026-02-26 (FY2025), source 26
FDA expects manufacturers to address cybersecurity risks in connected medical device design and post-market management=
Compliance with environmental health and safety laws may require substantial costs and facility operational changes=
Senior Credit Facility matures March 24, 2028; company expects to seek refinancing in 2026; covenant requirement dropping from 5.00 to 4.75 for Q3 2026=
Goodwill impairment of $511.4 million recorded; Consolidated Total Leverage Ratio at 4.50 with covenant requirement at 5.00; continued impairment risk if stock price or macroeconomic conditions deteriorate=
May need to refinance existing debt in 2026; may not be able to refinance on acceptable terms.=
Medicare payment methodology changes for skin substitute products may significantly alter reimbursement rates=
Tariff uncertainty and trade restrictions could increase manufacturing costs and disrupt supply chain.=
MediHoney quality and operational issues impacting Tissue Technologies segment; CSF Management shipping holds in prior year=
Collagen derived from bovine tissue subject to BSE concerns; potential for product bans or additional regulation=
Increased ethylene oxide regulations may reduce sterilization supplier capacity affecting product availability.=
Anti-kickback and false claims laws strictly regulate marketing practices and customer arrangements=
Import-export control and economic sanctions laws restrict sales to certain countries and entities=
PMA application processes for SurgiMend and DuraSorb may be time-consuming and expensive with uncertain approval timelines=
Changes to cleared devices requiring new 510(k), de novo or PMA approval may extend development timelines=
Evolving data privacy and cybersecurity regulations including EU AI Act impose increasing compliance costs.=
Failure to meet publicly announced environmental, social and governance goals risks reputation damage.=
U.S. Foreign Corrupt Practices Act and international anti-bribery laws create compliance risks.=
Global operations exposed to foreign currency exchange rate risk in Euros, British pounds, Swiss francs, and other currencies; managed through forward contracts and natural offsets=
Government and private sector initiatives to limit healthcare costs through price regulation and competitive bidding=
Intense competition for skilled personnel in sales, manufacturing, regulatory, and scientific positions.=
Products from bovine/porcine sources subject to additional regulation due to BSE/TSE transmission concerns.=
Adoption of AI tools by threat actors may pose new and more sophisticated cybersecurity challenges.=
Increased price sensitivity among hospital customers seeking cost reductions through centralized purchasing=
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2025-10-30 (2025-Q3), source 25
Forward-looking statements reference litigation risks under Private Securities Litigation Reform Act=
Integra LifeSciences: first mention in 10-Q quarterly report of 2025-10-30 (2025-Q3), source 24
Multiple FDA warning letters related to quality system violations at manufacturing facilities in Mansfield, Princeton, and Plainsboro.2026-Q1
2026-05-05 28
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2025-07-31 (2025-Q2), source 23
U.S. tariffs imposed, appealed, and invalidated by Supreme Court February 2026; new 10% global tariff under Section 122 implemented with uncertain ultimate impact on supply chain and costsFY2025
2026-02-26 26
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2025-05-05 (2025-Q1), source 21
U.S. tariffs on imports announced in April 2025; Supreme Court invalidated tariff program in February 2026; new 10% global tariff under Section 122 announced.2026-Q1
2026-05-05 28
Integra LifeSciences: first mention in 10-Q quarterly report of 2025-05-05 (2025-Q1), source 20
Section 122 tariffs implementation creating material headwinds; guidance does not contemplate recovery2025-Q4
2026-02-26 27
2023 FDA warning letter related to Boston facility quality issues; voluntary global recall initiated May 2023 for products manufactured between March 2018 and May 2023.=
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2025-02-25 (2024-Q4), source 19
EU Medical Device Regulation compliance costs and implementation delays affecting margins2025-Q4
2026-02-26 27
Integra LifeSciences: first mention in 10-K annual report of 2025-02-25 (FY2024), source 18
Vulnerability in third-party enterprise software affecting multiple customers; ongoing investigation underway.FY2025
2026-02-26 26
Total consolidated external debt approximately $1.9 billion with Senior Credit Facility maturing March 24, 2028.FY2025
2026-02-26 26
Manufacturing facility consolidation and transfer initiatives may result in delays or implementation issues.FY2025
2026-02-26 26
Foreign Corrupt Practices Act and anti-bribery laws require care in international sales and business dealingsFY2025
2026-02-26 26
HIPAA privacy and security requirements impose criminal and civil liability for violationsFY2025
2026-02-26 26
Changes in macroeconomic conditions including inflation, rising interest rates, bank failures could negatively impact business.FY2025
2026-02-26 26
Intense competition from established and early-stage companies; competitors may have greater resources and effectiveness.FY2025
2026-02-26 26
Increased emphasis on cost-effective medical therapies could require price decreases and affect profitability.FY2025
2026-02-26 26
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2024-07-29 (2024-Q2), source 15
Reliance on Cincinnati facility for specialty surgical products; alternate supply sources activated but capacity constraints remain.2026-10-02 32
Integra LifeSciences: first mention in 10-K annual report of 2024-02-28 (FY2023), source 10
Cincinnati facility flooding causing extended production disruption through Q2 2027; asset impairment risk.2026-10-02 32
International manufacturing locations subject to additional regulatory challenges and risksFY2025
2026-02-26 26
EU GDPR and UK GDPR impose strict requirements on personal data processing with significant compliance and penalty risksFY2025
2026-02-26 26
FDA inspections resulting in Form 483 observations, warning letters could affect manufacturing and product supply.FY2025
2026-02-26 26
Voluntary recalls including 2023 global Boston facility recall and 2024 recalls of cottonoid products and MediHoney.FY2025
2026-02-26 26
Exposure to interest rate fluctuations on SOFR-indexed borrowings with $900.0 million in interest rate swaps.2026-Q1
2026-05-05 28
Government and third-party payors reducing reimbursement rates or coverage scope could adversely affect product sales.FY2025
2026-02-26 26
Medical device industry characterized by extensive intellectual property litigation which could be costly.FY2025
2026-02-26 26
U.S. healthcare reform initiatives including OBBBA projected to decrease federal healthcare spending $1.0 trillion.FY2025
2026-02-26 26
Technological advances by competitors could render current products obsolete or uneconomical.FY2025
2026-02-26 26
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2023-10-25 (2023-Q3), source 9
Voluntary global recall of products manufactured at Boston facility between March 1, 2018 and May 22, 2023 including PriMatrix, SurgiMend, Revize, and TissueMend2025-Q3
2025-10-30 24
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2023-07-27 (2023-Q2), source 7
Amount of bank borrowings and other factors influencing liquidity may fluctuate.2026-Q1
2026-05-05 29
Worldwide macroeconomic and geopolitical uncertainty may adversely affect business and prospects.FY2025
2026-02-26 26
Integra LifeSciences: first mention in 10-Q quarterly report of 2023-07-27 (2023-Q2), source 6
Quality and operational issues at multiple manufacturing facilities impacting revenue and gross margin; enterprise-wide Compliance Master Plan implemented across manufacturing networkFY2025
2026-02-26 26
Integra LifeSciences: first mention in 8-K-EX99.1 earnings release of 2023-04-26 (2023-Q1), source 5
Difficulties in implementing compliance master plan and remediating quality systems violations may impact regulatory approvals.2026-Q1
2026-05-05 29
Global challenges including inflation and geopolitical conflicts affecting suppliers and customers2025-Q4
2026-02-26 27
Integra LifeSciences: first mention in 10-Q quarterly report of 2023-04-26 (2023-Q1), source 4
Hazardous materials regulations and environmental laws may increase compliance costs.FY2025
2026-02-26 26
No single customer represented more than 10% of 2025 consolidated revenuesFY2025
2026-02-26 26
= last mention identical with the first mention (same source)

Integra LifeSciences Reported KPIs (as disclosed) (190)

The story KPIs of Integra LifeSciences that standard databases usually miss, grouped by publication, most recent first, with source number. NadirAlpha methodology

Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
Integra LifeSciences: reported KPIs as disclosed, 190 entries. Compiled by NadirAlpha from SEC filings.
KPIValue / changeSource
Integra LifeSciences, published 2026-10-02, period 2026-Q3
revenue Q3 preliminaryapproximately $410 million to $412 million32
operating cash flow Q3greater than $85 million32
flooding impact Q4 revenueapproximately $15 million to $20 million32
flooding impact Q3 revenueapproximately $7 million32
Integra LifeSciences, published 2026-07-29, period 2026-Q2
Total Liquidityapproximately $496 million31
Consolidated Total Leverage Ratio4.1x31
Tissue Reconstruction Revenue$109,49230
Specialty Surgery Revenue$309,26930
Short-Term Investments$59.730
Selling, General and Administrative as % of Revenue41.2%30
Research and Development as % of Revenue5.8%30
Operating Cash Flow$32,60530
IEEPA Tariff Refund Claims Submitted$17.630
Gross Margin Percentage52.5%30
Consolidated Total Leverage Ratio4.1030
Cash and Cash Equivalents$214.430
Capital Expenditures$27.230
Integra LifeSciences, published 2026-05-05, period 2026-Q1
Working Capital825.2 million28
Total Liquidity$488 million29
Short-Term Investments28.7 million28
Organic Revenue Growth Q11.3%29
Organic Revenue Growth0.8% to 3.3%29
Non-US Cash196.9 million28
Net Debt$1.6 billion29
Gross Margin GAAP55.4%29
Consolidated Total Leverage Ratio Covenant5.0028
Consolidated Total Leverage Ratio4.1228
Consolidated Total Leverage Ratio4.1x29
Cash and Short-Term Investments$265.5 million29
Cash and Equivalents236.8 million28
Adjusted Gross Margin64.1%29
Adjusted EBITDA Margin19.4%29
Integra LifeSciences, published 2026-02-26, period FY2025
Working Capital$703.6 million26
Valuation Allowance Deferred Tax Assets$22.6 million26
State Net Operating Loss Carryforwards$85.4 million26
Non-US Cash and Equivalents$193.0 million26
Gross Deferred Tax Assets$278.1 million26
Foreign Net Operating Loss Carryforwards$142.8 million26
Federal Net Operating Loss Carryforwards$46.7 million26
Consolidated Total Leverage Ratio4.5026
Integra LifeSciences, published 2026-02-26, period 2025-Q4
Total Liquidityapproximately 516 million27
Consolidated Total Leverage Ratio4.5x27
Cash and Short-Term Investments263.7 million27
adjusted gross margin61.7%27
adjusted gross margin65.2%27
adjusted gross margin61.9%27
adjusted gross margin64.5%27
adjusted EBITDA margin24.0%27
adjusted EBITDA margin23.7%27
adjusted EBITDA margin19.4%27
adjusted EBITDA margin19.4%27
Integra LifeSciences, published 2025-10-30, period 2025-Q3
Total Liquidity$549.8 million25
total debt$1.8 billion25
operating cash flow Q3$40.9 million25
Net Debt$1.6 billion25
Consolidated Total Leverage Ratio4.3x25
Cash and Short-Term Investments$267.9 million25
Adjusted Gross Margin62.9%25
GAAP gross margin51.5%25
covenant requirement5.0024
Consolidated Total Leverage Ratio4.3524
Integra LifeSciences, published 2025-07-31, period 2025-Q2
Total Liquidity1.14 billion23
Net Debt1,591,13023
Consolidated Total Leverage Ratio4.5x23
adjusted gross margin60.7%23
adjusted gross margin65.2%23
working capital213.0 million22
short-term investments35.7 million22
non-U.S. subsidiaries cash180.0 million22
covenant requirement5.0022
Consolidated Total Leverage Ratio4.5322
Cash and Cash Equivalents217.9 million22
Integra LifeSciences, published 2025-05-05, period 2025-Q1
Working Capital188.8 million20
Short-Term Investments34.2 million20
non-U.S. subsidiaries cash and cash equivalents182.7 million20
cash and cash equivalents239.1 million20
Total liquidity1.16 billion21
Total leverage ratio4.3x21
GAAP gross margin50.8%21
Consolidated Total Leverage Ratio covenant requirement5.0020
Consolidated Total Leverage Ratio4.3020
Cash and short-term investments273 million21
Integra LifeSciences, published 2025-02-25, period FY2024
Working Capital159.6 million18
Valuation allowance15.5 million18
Short-term investments interest rate sensitivity0.3 million18
Short-Term Investments27.2 million18
Net operating loss carryforwards state46.5 million18
Net operating loss carryforwards foreign106.7 million18
Net operating loss carryforwards federal51.2 million18
Impairment charge Boston4.6 million18
Estimated effective tax rate36.7%18
Effective tax rate61.9%18
Effective tax rate16.4%18
Debt interest rate sensitivity8.1 million18
Consolidated Total Leverage Ratio4.0418
Cash interest rate sensitivity2.5 million18
Cash and Equivalents246.4 million18
Integra LifeSciences, published 2025-02-25, period 2024-Q4
Total Liquidityapproximately 1.2 billion19
Net Debt1.5 billion19
Consolidated Total Leverage Ratio4.0x19
Cash and Short-Term Investmentsapproximately 273 million19
Integra LifeSciences, published 2024-11-04, period 2024-Q3
Revenue$380.8 million16
Gross margin52.6%16
Consolidated Total Leverage Ratio3.9916
Total liquidity$1.18 billion17
Total balance sheet debt$1.81 billion17
GAAP gross margin52.6%17
Consolidated total leverage ratio4.0x17
Cash and short-term investments$277 million17
Adjusted EBITDA margin16.2%17
Integra LifeSciences, published 2024-07-29, period 2024-Q2
Working capital$784.014
Total revenues$418,17514
Total liquidity1.18 billion15
Total balance sheet debt1.83 billion15
Tissue Technologies segment revenue116,41415
Tissue Technologies organic growth5.7%15
Short-term investments$81.714
Organic growth excluding Boston0.3%15
Organic growth2.3%15
Gross margin on total revenues$225,91714
Gross margin as % of total revenues54.0%14
Consolidated total leverage ratio3.8x15
Codman Specialty Surgical segment revenue301,76115
Codman Specialty Surgical organic growth0.9%15
Cash and short-term investments297 million15
Cash and cash equivalents$215.214
Adjusted EBITDA margin20.0%15
Integra LifeSciences, published 2024-05-06, period 2024-Q1
Working Capital$1,113.3 million12
Short-Term Investments$71.2 million12
Cash, non-US subsidiaries$210.6 million12
Cash and equivalents, total$591.9 million12
Total liquidityapproximately $1.54 billion13
Total balance sheet debt$1.86 billion13
Tissue Technologies revenues$112.4 million13
Neurosurgery organic growth6.3%13
Consolidated total leverage ratio3.2x13
Codman Specialty Surgical revenues$256.4 million13
Cash plus short-term investments$663 million13
Integra LifeSciences, published 2024-02-28, period FY2023
Working capital751.1 million10
Working capital840.6 million10
short term investments32.7 million10
non-US cash246.9 million10
cash and cash equivalents276.4 million10
cash and cash equivalents456.7 million10
Integra LifeSciences, published 2024-02-28, period 2023-Q4
Total liquidity1.5 billion11
Organic revenue growth full-year excl. Boston5.5%11
Organic revenue growth full-year0%11
Organic revenue growth Q4 excl. Boston3.6%11
Organic revenue growth Q4-1.2%11
Net debt1.2 billion11
Consolidated total leverage ratio3.0x11
Cash and short-term investments309 million11
Adjusted EBITDA margin full-year24.0%11
Adjusted EBITDA margin Q425.3%11
Integra LifeSciences, published 2023-10-25, period 2023-Q3
Working Capital671.5 million8
unsatisfied performance obligations50%8
non-US subsidiaries cash247.7 million8
deferred compensation plan fair value5.4 million8
contract liability short-term8.1 million8
contract liability long-term8.1 million8
cash and cash equivalents273.7 million8
Total liquidity$1.48 billion9
GAAP gross margin prior year61.5%9
GAAP gross margin57.1%9
Consolidated total leverage ratio3.0x9
Cash and cash equivalents273,7329
Adjusted gross margin prior year66.7%9
Adjusted gross margin64.6%9
Adjusted EBITDA margin prior year27.3%9
Adjusted EBITDA margin23.0%9
Integra LifeSciences, published 2023-07-27, period 2023-Q2
working capital June 30673.8 million6
working capital Dec 31840.6 million6
non-US subsidiaries cash June 30267.1 million6
cash and cash equivalents June 30309.2 million6
cash and cash equivalents Dec 31456.7 million6
Total liquidity1,610,0007
Total balance sheet debt1,440,0007
Reported revenue growth-4.2%7
Organic revenue growth excluding Boston recall5.5%7
Organic revenue growth-2.7%7
GAAP gross margin54.3%7
Consolidated total leverage ratio2.6x7
Adjusted gross margin67.6%7
Adjusted EBITDA margin23.3%7
Integra LifeSciences, published 2023-04-26, period 2023-Q1
Total Liquidityapproximately $1.61 billion5
total debt$1.45 billion5
operating cash flow26,1565
Net Debt$1.15 billion5
Consolidated Total Leverage Ratio2.5x5
Cash and Equivalents$307 million5

Integra LifeSciences Development

A condensed summary of Integra LifeSciences per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. NadirAlpha methodology

FY2026: Integra LifeSciences

Integra LifeSciences generated 391.9 million in first-quarter 2026 revenues, representing reported growth of 2.4% and organic growth of 1.3% compared to the prior year 29, followed by 418.8 million in the second quarter with reported growth of 0.8% and organic growth of 0.7% 31. Gross margin improved in both quarters, driven primarily by reduced Braintree remediation costs and improved manufacturing performance 28 30, while adjusted EPS reached 0.54 in Q1 29 and 0.56 in Q2 31. The GAAP net position recovered from a net loss of 4.6 million in Q1 29 to net income of 4.5 million in Q2, the latter reflecting the absence of a prior-year goodwill impairment charge 30. A flood at the Cincinnati, Ohio manufacturing facility on July 17, 2026 disrupted specialty surgical technologies production, prompting the company to lower full-year revenue guidance to $1.634 to $1.654 billion and cut adjusted EPS guidance from $2.40 to $2.50 to $2.30 to $2.40, while confirming full-year operating cash flow guidance of approximately $190 to $200 million 32.

FY2025: Integra LifeSciences

Integra LifeSciences reported FY2025 total revenues of $1,635.2 million, up 1.5% on a reported basis but down 0.7% organically, with the Codman Specialty Surgical segment growing 5.0% offset by a Tissue Technologies segment decline of 6.9% 26. Gross margin fell from 54.8% in 2024 to 50.9%, reflecting quality and operational disruptions tied to an FDA warning letter received December 2024, higher manufacturing costs, and $19.9 million in tariff costs 26. A non-cash goodwill impairment of $511.4 million recorded in Q2 2025 across the Tissue Technologies, Neurosurgery, and Instruments and ENT reporting units, driven by share price decline and operational challenges, produced a GAAP net loss of $516.5 million for the year, while adjusted EPS declined to $2.23 from $2.56 in 2024 26 27. Operating cash flow fell $79.0 million to $50.4 million and free cash flow was negative $31.1 million, weighed by higher manufacturing costs and tariff payments 26. The Acclarent ENT acquisition completed April 2024 contributed to Codman Specialty Surgical revenue growth, while the Braintree manufacturing facility remained on track for mid-2026 operationalization to support pending SurgiMend and DuraSorb PMA approvals 26.

FY2024: Integra LifeSciences

Integra LifeSciences reported FY2024 total revenues of $1,610.5 million, up 4.5% on a reported basis from $1,541.6 million in 2023, with the Acclarent acquisition–completed April 1, 2024 for approximately $282 million–accounting for the majority of reported growth; on an organic basis revenues declined approximately 1.3%, as quality and operational disruptions including temporary shipping holds implemented mid-year and the ongoing impact of the voluntary Boston facility product recall suppressed volume, most acutely in Neurosurgery during Q3 18 19. Full-year gross margin contracted to 54.8% from 57.4%, reflecting Boston recall-related charges, Acclarent inventory step-up amortization, and underutilized manufacturing capacity 18. GAAP net loss was $6.9 million versus net income of $67.7 million in 2023, while adjusted EPS declined to $2.56 from $3.10 and full-year adjusted EBITDA margin compressed approximately 400 basis points to 20.0% 18 19. Additional developments during the year included the October 2024 acquisition of Durepair Regeneration Matrix product rights for $45 million, an FDA warning letter issued in December 2024 regarding quality system issues at three manufacturing facilities, and the planned transition of PriMatrix and SurgiMend manufacturing to a new Braintree, Massachusetts facility targeted for first-half 2026 operationalization 18.

FY2023: Integra LifeSciences

Integra LifeSciences reported FY2023 revenues of $1,541.6 million, a decline of 1.0% on a reported basis and flat organically versus $1,557.7 million in FY2022, with growth in the Codman Specialty Surgical segment offset by a significant decline in the Tissue Technologies segment driven by the Boston manufacturing facility recall 10 11. The voluntary recall of Boston-manufactured products distributed between March 2018 and May 2023 resulted in a $24.6 million inventory write-off, an $18.7 million product return provision, and $15.0 million in idle capacity charges, compressing gross margin to 57.4% from 62.3% in the prior year 10. The Codman Specialty Surgical segment grew $39.4 million (3.9%), while the Tissue Technologies segment declined $55.5 million (10.3%); excluding the Boston recall and TWC divestiture impacts, the Tissue Technologies segment increased approximately $32.0 million driven by strong sales in IDRT and MicroMatrix/Cytal 10. Net income decreased to $67.7 million ($0.84 per diluted share) from $180.6 million ($2.16 per diluted share) in FY2022, with adjusted EPS of $3.10 compared to $3.36 in the prior year and full-year adjusted EBITDA declining $41.6 million to $369.7 million 10 11. In December 2023, the company signed a definitive agreement to acquire Acclarent Inc. from Johnson & Johnson for $275 million cash plus up to $5 million in regulatory milestone payments, targeting completion by Q2 2024 10.

Glossary

  • Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
  • Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
  • EBITDA (adj.): Adjusted EBITDA, verbatim and company-defined (non-GAAP), never derived.
  • Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
  • EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
  • EPS adj.: Adjusted earnings per share, verbatim and company-defined (non-GAAP).
  • FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
  • OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
  • Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
  • Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
  • *: derived, the formula is in the hover
  • ≈: calculated, approximation
  • ~: uncertain; the value stays visible, verdicts do not use it
  • °: repaired by a targeted query against the document, or curated with documentary evidence
  • EBIT: EBIT as a fallback: the income statement carries no operating line
  • basic: basic earnings per share as a fallback when diluted is missing

Sources: quarterly reports, annual reports and investor relations documents

50 sources on Integra LifeSciences since 2023; the superscript numbers in the chapters refer to these rows, older documents are in the expandable part. NadirAlpha methodology

50 documents · 2016 to 2026 · SEC EDGAR (USA)
Sources for Integra LifeSciences stock: 50 original documents, 2016 to 2026. Compiled by NadirAlpha.
#Document typePublished
#18-K-EX99.1 earnings release2023-01-10
#210-K annual report2023-02-22
#3 / #1038-K-EX99.1 earnings release2023-02-22
#410-Q quarterly report2023-04-26
#5 / #1058-K-EX99.1 earnings release2023-04-26
#610-Q quarterly report2023-07-27
#7 / #1078-K-EX99.1 earnings release2023-07-27
#8 / #10810-Q quarterly report2023-10-25
#9 / #1098-K-EX99.1 earnings release2023-10-25
#1010-K annual report2024-02-28
#11 / #1118-K-EX99.1 earnings release2024-02-28
#1210-Q quarterly report2024-05-06
#13 / #1138-K-EX99.1 earnings release2024-05-06
#1410-Q quarterly report2024-07-29
#15 / #1158-K-EX99.1 earnings release2024-07-29
#1610-Q quarterly report2024-11-04
#17 / #1178-K-EX99.1 earnings release2024-11-04
#1810-K annual report2025-02-25
#19 / #1198-K-EX99.1 earnings release2025-02-25
#2010-Q quarterly report2025-05-05
#21 / #1218-K-EX99.1 earnings release2025-05-05
#2210-Q quarterly report2025-07-31
#23 / #1238-K-EX99.1 earnings release2025-07-31
#2410-Q quarterly report2025-10-30
#25 / #1258-K-EX99.1 earnings release2025-10-30
#2610-K annual report2026-02-26
#27 / #1278-K-EX99.1 earnings release2026-02-26
#2810-Q quarterly report2026-05-05
#29 / #1298-K-EX99.1 earnings release2026-05-05
#3010-Q quarterly report2026-07-29
#31 / #1318-K-EX99.1 earnings release2026-07-29
#328-K-EX99.1 earnings release2026-10-02
Older sources (+18)
Older sources for Integra LifeSciences, 18 documents
#Document typePublished
#20110-Q quarterly report2016-04-27
#20210-Q quarterly report2016-07-28
#20310-Q quarterly report2016-10-28
#20410-K annual report2017-02-23
#20610-Q quarterly report2017-02-23
#20710-K annual report2017-02-23
#20510-Q quarterly report2017-07-26
#20910-K annual report2018-03-01
#20810-Q quarterly report2018-07-26
#21110-K annual report2019-02-26
#21010-Q quarterly report2019-07-25
#21510-K annual report2020-02-21
#21210-Q quarterly report2020-05-07
#21310-Q quarterly report2020-08-10
#21410-Q quarterly report2020-10-29
#21610-Q quarterly report2021-04-29
#21710-Q quarterly report2021-07-29
#21810-Q quarterly report2021-11-02

Integra LifeSciences Stock FAQ

Is there a management forecast (guidance) for FY2026?

Yes. Management has issued targets for FY2026, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.

Which additional key figures does Integra LifeSciences report?

As reported for Q2 2026: Consolidated Total Leverage Ratio, Tissue Reconstruction Revenue, Specialty Surgery Revenue, Short-Term Investments, Selling, General and Administrative as % of Revenue, Research and Development as % of Revenue. The chapter Reported KPIs lists every value with its source. Revenue is broken down by Specialty Surgery, Tissue Reconstruction, ENT, Neurosurgery.

Where can I find the official investor relations documents of Integra LifeSciences?

NadirAlpha links all 50 original filings used (SEC filings) in the sources chapter: earnings release, quarterly report, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.

More reports by NadirAlpha

Recently updated

Ahold Delhaize (1AD)NL0011794037Figures as of Updated Revenue decelerating · Margin compressingAdobe (ADBE)US00724F1012Figures as of Updated Acquisition · Net cash to net debtAixtron (AIXA.DE)DE000A0WMPJ6Figures as of Updated Margin expanding · Cash flow inflection

Comparable stocks by NadirAlpha

Constellation Energy (CEG)US21037T1097Figures as of Updated Revenue decelerating · Guidance raisedColumbus McKinnon (CMCO)US1993331057Figures as of Updated Revenue accelerating · Order intakeFactSet Research Systems (FDS)US3030751057Figures as of Updated New marketIntel (INTC)US4581401001Figures as of Updated Acquisition · Revenue acceleratingGartner (IT)US3666511072Figures as of Updated Margin expandingMercadoLibre (MELI)US58733R1023Figures as of Updated Revenue accelerating · New market

All reports · US Stocks (43)